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a significant predictive value in addition to established prog-
nostic factors in MDS. Leukemic growth identifies a subpop-
ulation of MDS patients with poor prognosis. 
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 Introduction 
 Myelodysplastic syndromes (MDS) are characterized 
by maturation defects in one or several hematopoietic cell 
lineages resulting in peripheral blood (PB) cytopenia  [1, 
2] . The clinical course varies from chronic mild anemia, 
thrombocytopenia or leukopenia to rapid leukemic trans-
formation and death. Treatment options range from sup-
portive care (transfusions and hematopoietic growth fac-
tors) in patients with symptomatic cytopenia to immu-
nosuppressive therapy with ATG/cyclosporine, if an 
autoimmune component is suspected, or AML-like che-
motherapy for patients with elevated blast cell counts. 
Cure can be achieved with hematopoietic stem cell trans-
plantation in younger patients  [3] . More recently, drugs 
such as demethylating agents and immunomodulatory 
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 Abstract 
 In patients with myelodysplastic syndrome (MDS) precursor 
cell cultures (colony-forming unit cells, CFU-C) can provide 
an insight into the growth potential of malignant myeloid 
cells. In a retrospective single-center study of 73 untreated 
MDS patients we assessed whether CFU-C growth patterns 
were of prognostic value in addition to established criteria. 
Abnormalities were classified as qualitative (i.e. leukemic 
cluster growth) or quantitative (i.e. strongly reduced/absent 
growth). Thirty-nine patients (53%) showed leukemic 
growth, 26 patients (36%) had strongly reduced/absent col-
ony growth, and 12 patients showed both. In a univariate 
analysis the presence of leukemic growth was associated 
with strongly reduced survival (at 10 years 4 vs. 34%, p = 
0.004), and a high incidence of transformation to AML (76 vs. 
32%, p = 0.01). Multivariate analysis identified leukemic 
growth as a strong and independent predictor of early death 
(relative risk 2.12, p = 0.03) and transformation to AML (rela-
tive risk 2.63, p = 0.04). Quantitative abnormalities had no 
significant impact on the disease course. CFU-C assays have 
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drugs have become available; they possibly improve the 
outlook for MDS patients not eligible for more intensive 
treatment  [4] .
 The choice of treatment for individual patients de-
pends on diagnostic and prognostic criteria, the age of 
the patient, and availability of a stem cell donor. The 
WHO disease classification  [5] and the International 
Prognostic Scoring System (IPSS score)  [6] have largely 
replaced the original French-American-British (FAB) 
classification of MDS  [7, 8] . Favorable prognostic factors 
include maturation defects restricted to one cell line, low 
myeloblast count, absence of cytogenetic abnormalities 
or presence of certain alterations such as isolated deletion 
of 5q  [9, 10] , and presence of ringed sideroblasts  [11] . On 
the other hand, multilineage dysplasia, a high blast count, 
cytogenetic abnormalities such as those involving chro-
mosome 7 and presence of a complex karyotype are poor 
prognostic signs  [12, 13] . The WHO classification and the 
IPSS score are currently used to assess the prognosis of 
an individual patient and are the basis for therapeutic de-
cisions  [14, 15] .
 Less broadly accepted prognostic factors include bone 
marrow (BM) hypocellularity as a favorable factor  [16] 
and BM fibrosis as an adverse factor  [17, 18] . More re-
cently the prognostic significance of several other pa-
rameters, such as LDH value  [19] and DNA microarray 
analysis  [20, 21], have been investigated. Their indepen-
dent prognostic value remains to be established. Despite 
these advances the prediction of outcome and thus the 
choice of adequate primary treatment often remain un-
satisfactory, particularly for patients classified to be at 
‘intermediate risk’, representing the majority of MDS pa-
tients  [1, 22, 23] .
 Soon after the detection of the colony-forming precur-
sor cell, colony-forming unit cell (CFU-C) assays became 
a useful diagnostic tool in the clinical assessment of pa-
tients with AML and MDS. Quantitative and qualitative 
abnormalities were recognized. Lower numbers of nor-
mal colonies and grossly abnormal erythroid colonies 
 [24] were found to be typical of MDS, and the growth of 
leukemic clusters in culture soon became an acknowl-
edged sign of treatment resistance in AML  [25] and of 
impending leukemic transformation in MDS  [26, 27] , 
particularly in patients with autocrine growth factor-in-
dependent leukemic proliferation  [28, 29] . However, as 
hematopoietic precursor cell cultures proved difficult to 
standardize  [30] they were gradually replaced by other 
techniques, and only limited data are available on the im-
pact of the colony-forming assay in the contemporary 
management of MDS  [31] .
 In a retrospective study we therefore examined the 
value of quantitative and qualitative abnormalities in 
growth properties of CFU-C derived from BM and PB of 
untreated MDS patients and compared it to established 
prognostic factors.
 Patients and Methods 
 Patients and Study Design 
 This single-center retrospective study included 73 consecutive 
patients receiving a first diagnosis of MDS between July 1992 and 
June 2002. The patients fulfilled all three of the following crite-
ria: 
 (1 ) Diagnosis of MDS according to WHO criteria.  
(2 ) Complete workup at first diagnosis including PB counts, BM 
aspirate and trephine biopsy, CFU-C cultures from BM and 
PB, and cytogenetic analysis as part of the routine panel of 
tests performed in a patient with suspected MDS at our insti-
tution. 
(3 ) Availability of follow-up data on disease course after initial 
diagnosis.  
 BM and PB from 40 healthy BM donors were used for control 
CFU-C cultures after informed consent had been obtained.
 As diagnostic criteria for MDS changed from FAB to WHO 
classification during the period in which patients were diagnosed, 
all records were reevaluated and patients classified according to 
the WHO classification. Patients no longer classified as having 
MDS according to WHO [i.e. those with a FAB diagnosis of 
chronic myelomonocytic leukemia and refractory anemia with 
excess blasts-1 in transformation (RAEB-t)] were excluded from 
the study.
 The median age of the patients at diagnosis was 66 years (range 
13–88); 43 (58.9%) of the patients were male. The median obser-
vation period was 2.8 years (range 0.1–12 years). At last follow-up 
56 patients (77%) had died and 17 patients (23%) were alive. Di-
agnoses according to the WHO were refractory anemia with or 
without ringed sideroblasts in 4 patients (5.5%), refractory cyto-
penia with multilineage dysplasia with or without ringed sidero-
blasts in 24 patients (32.9%), RAEB-1 in 24 patients (32.9%), 
RAEB-2 in 19 patients (26%), and MDS unclassified in 2 patients 
(2.7%). Cytogenetics were ‘good risk’ (i.e. normal karyotype or 
isolated del(5q), del(20q) or -Y) in 46 patients (63%), ‘bad risk’ (i.e. 
chromosome 7 abnormalities or complex karyotype) in 15 pa-
tients (20.5%), and ‘intermediate risk’ in the remaining 12 pa-
tients (16.4%). Risk status according to the IPSS was ‘low’ in 12 
patients (16.4%), ‘intermediate-1’ in 34 patients (46.6%), ‘interme-
diate-2’ in 20 patients (20.7%), and ‘high’ in 7 patients (9.6%).
 Treatment Modalities 
 The treatment approach was consistent throughout the obser-
vation period. Whenever possible, patients were treated accord-
ing to a formal protocol: patients at low risk of transformation and 
those not able to undergo more intensive therapy received sup-
portive care (transfusions, treatment of infections, hematopoietic 
growth factors); immunosuppressive therapy with antithymocyte 
globulin/cyclosporine was offered as part of an ongoing trial to 
patients with a suspected autoimmune cytopenia component; pa-
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tients with elevated blast count and/or impending transformation 
were treated with AML-like chemotherapy. Younger patients 
with progressive disease were offered allogeneic hematopoietic 
stem cell transplantation if a matched sibling or unrelated donor 
was available.
 BM Morphology and Histology 
 BM biopsy and aspiration were performed at the posterior su-
perior iliac crest. Biopsy material was fixed in formalin, embedded 
and stained with hematoxylin/eosin for assessment of morpholo-
gy and with silver for visualization of fibers. Aspirated material 
was stained with Wright/Giemsa and iron stain. BM morphology 
was assessed for cellularity, dysplastic changes, percentage of blast 
cells, and the presence of ring sideroblasts and fibrosis.
 Cytogenetic Analysis 
 Cell culture and chromosome preparation were performed on 
BM or PB samples as reported previously  [32, 33] . Chromosomes 
were stained in G bands. Karyotypes were described according to 
the International System for Human Cytogenetic Nomenclature 
 [34] .
 CFU Cultures 
 Culture Media 
 600,000 PB and 100,000 BM cells/ml of culture, respectively, 
were obtained from heparinized PB and marrow by Ficoll cen-
trifugation. The untreated adherent cell-containing suspension 
was washed and cultured in duplicates in commercial methylcel-
lulose medium supplied by StemCell Technologies, Vancouver, 
B.C., Canada (MethoCult TM GH H4431) containing 30% fetal bo-
vine serum, 1% bovine serum albumin, 10 –4  M mercaptoethanol, 
2 m M  L -glutamine, 50 ng/ml SCF, 10 ng/ml GM-CSF, 10 ng/ml 
IL-3, 3 U erythropoietin/ml and 70% Iscove’s modified Dulbec-
co’s medium for 14 days in a fully humidified atmosphere at 37 ° C 
supplemented with 5% CO 2 . 
 Quantification and Morphology of Cultures 
 After incubation, colonies were counted in an inverted micro-
scope. The number of CFU-granulocyte, CFU-eosinophil, CFU-
macrophage, burst-forming unit-erythroid (BFU-E), and mixed 
colonies was counted and added to give a total number of colonies. 
For quantitative analysis, the total number of normal CFU-C was 
compared to normal ranges derived from a population of healthy 
donors, independent of colony size, hemoglobinization of BFU-E, 
E:M ratio and the presence or absence of leukemic clusters. In 
agreement with standard laboratory practice, we defined the 
2.5th and 97.5th percentiles of healthy donors’ CFU-C counts as 
lower and upper limits of the normal range. Accordingly, patients 
with CFU-C counts below the 2.5th percentile (i.e.  ! 8 CFU-
C/600,000 PB cells or  ! 20 CFU-C/100,000 BM cells) were consid-
ered to have a quantitative growth defect. Culture technique and 
evaluation of healthy donor BM and PB cultures are subject to 
international standardization and quality control with yearly ring 
experiments performed at our institution.
 As higher than normal CFU-C counts (i.e.  1 112 CFU-C in PB 
or  1 235 CFU-C in BM) are almost exclusively seen in patients also 
displaying leukemic growth, this abnormality was not assessed 
separately.
 Leukemic cluster growth in cultures is characterized by cell 
agglomerations of visibly abnormal individual nonhemoglo-
binized cells of varying size, resembling either granulocytes or 
macrophages (verified by May-Grünwald-Giemsa staining of in-
dividual clusters in case of doubt). In addition to morphological 
abnormalities, leukemic clusters can be differentiated from colo-
nies by their smaller cell number (typically  ! 40 per cluster com-
pared to  1 50 per colony). Counting of leukemic clusters does not 
give an appropriate estimate of the proliferative potential of leu-
kemic precursors because the dispersion of leukemic growth var-
ies individually. We therefore judged leukemic growth as an all-
or-none phenomenon. A minimum of 20 leukemic clusters in cul-
tures also containing normal colonies and 10 clusters in otherwise 
empty cultures were used as cut points. In cases of doubt, indi-
vidual clusters or colonies were selected and stained to reveal ei-
ther leukemic or normal myeloid morphology.
 For qualitative analysis, the presence of leukemic cluster 
growth ( fig. 1 c–f) in either BM or PB culture was considered ab-
normal. For quantitative analysis, reduced growth in both PB and 
marrow was considered abnormal.
 Statistical Analysis 
 The cohorts stratified by the CFU-C growth pattern were 
compared using Pearson’s   2 test for discontinuous and Mann-
Whitney test for continuous variables. Rates of overall survival 
and transformation to AML were estimated using the Kaplan-
Meier method and compared by log rank test. Cox proportional 
hazards models were used to estimate the impact of individual 
prognostic factors on multivariate analysis. Patients receiving al-
logeneic hematopoietic stem cell transplantation were censored 
for follow-up on the day of the transplant.
 Results 
 Quantitative CFU Abnormalities in MDS Patients 
 Comparison of CFU-C numbers in PB and marrow of 
healthy controls and MDS patients showed lower median 
CFU-C, and a wider range of values in both PB and mar-
row in patients than in controls ( table 1;  fig. 2 ). Reduction 
of CFU-C was more pronounced for BFU-E than for my-
eloid CFU-C, resulting in a reduction of the erythroid:
myeloid ratio. Twenty-six of 73 patients (36%) showed 
CFU-C numbers in both PB and marrow within the nor-
mal range of healthy donors’ values and were therefore 
classified as quantitatively normal, even if they had leu-
kemic cluster growth in addition to morphologically nor-
mal colonies. In 10 patients the growth of colonies was 
completely absent. The differences between colony num-
bers in normal and MDS patients were more marked for 
BM than for PB cultures, indicating that cultures from 
BM have a higher diagnostic power in MDS and cannot 
be replaced by cultures from PB. Several patients had nor-
mal colony growth in PB cultures. Compared with pa-
tients displaying normal numbers of CFU-C, patients 
with quantitative growth defects were more frequently 
found to have a reduced marrow cellularity, whereas all 
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a b
c d
e f
 Fig. 1. Representative examples of normal colonies and leukemic cluster growth in patients with MDS (all with 
100 ! magnification). Normal size and relationship between erythroid (solid arrow) and myeloid colonies (open 
arrows) in a healthy control donor ( a ) versus strong reduction of normal erythroid and myeloid colonies in MDS 
patients ( b–f ): single dispersed macrophages without leukemic growth ( b ), small leukemic clusters ( c ), growth 
of single isolated leukemic cells ( d ), large leukemic clusters ( e ), and leukemic clusters with dendritic cell mor-
phology ( f ). 
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other prognostic factors were distributed equally ( ta-
ble 2 ). Despite quantitative abnormalities in MDS pa-
tients, no significant differences in disease characteris-
tics were seen between patients with strongly reduced 
and those with completely absent colony growth. An ex-
ample of quantitatively and qualitatively normal colony 
growth is shown in  figure 1 a.  Figure 1 b shows a culture 
with a quantitative defect (no colonies), growth of free 
macrophages and without leukemic growth.
 Qualitative CFU Abnormalities 
 Of the known qualitative growth abnormalities in-
cluding small colony size and inadequate hemoglobiniza-
tion of BFU-E, only leukemic alteration of CFU-GM was 
analyzed.  Figure 1 c–f show examples of leukemic growth, 
as observed in more than half of the patients (39/73, 53%). 
Compared to patients without leukemic growth, patients 
with leukemic CFU-C growth were significantly younger 
(60 vs. 71 years), had more frequently elevated blast counts 
and bad-risk cytogenetics, and were accordingly more 
frequently diagnosed with high-risk MDS according to 
WHO (RAEB-I and II) and IPSS (see  table 2 ).
 A significant proportion of patients showed both qual-
itative and quantitative abnormalities: of 39 patients with 
leukemic growth, 12 (31%) at the same time showed re-
duced/absent colony growth compared to 41% of patients 
without leukemic growth (p = 0.35). Only 2 patients had 
completely normal colony growth, including numbers, 
colony size, hemoglobinization of BFU-E, PB:BM and E:
M ratio and absence of leukemic clusters.
 Impact of CFU-C Abnormalities on Overall Survival 
in Univariate Analysis 
 Quantitative abnormalities of CFU-C had no measur-
able effect on the disease course: both median survival 
(1.70  8 0.26 vs. 1.91  8 0.42 years) and frequency of long-
term survivors (20  8 8 vs. 17  8 6%) were similar in pa-
tients with reduced and those with normal CFU-C num-
bers ( fig. 3 e). Equally, within the subgroup of patient with 
leukemic CFU-C growth, quantitative abnormalities had 
no impact with a median survival of 1.50  8 0.41 years for 
patients with leukemic clusters and reduced growth ver-
sus 1.45  8 0.40 years for patients with leukemic clusters 
and quantitatively normal colony growth (p = 0.71).
 On the other hand the presence of leukemic cell growth 
significantly predicted a worse disease course: patients 
with leukemic cells had a median survival of 1.45 years 
( 8 0.31) compared to 2.88 years ( 8 1.75) in patients without 
leukemic growth ( fig. 3 a, p = 0.0004). Estimated 10-year 
overall survival was 34% ( 8 8) in patients without com-
pared to only 4% ( 8 4) in patients with leukemic CFU-C 
growth. Four patients with leukemic growth were alive at 
Table 1. CFU-C assays in healthy donors and MDS patients
Healthy controls Patients p
median range median range
Peripheral blood
CFU-G 7 0–30 4 0–202 0.23
CFU-M/GM 1 0–6 0 0–129 0.21
CFU-Eo 0 0–9 0 0–13 0.39
BFU-E 36 4–93 4 0–336 <0.001
CFU-GEMM 0 0–7 0 0–8 0.006
Total 46 6–115 15 0–388 <0.001
E:M ratio 3.6 1.0–14 0.62 0–97 <0.001
Bone marrow
CFU-G 25 7–72 6 0–192 <0.001
CFU-M/GM 27 1–120 2 0–192 <0.001
CFU-Eo 1 0–19 0 0–8 <0.001
BFU-E 35 8–96 2 0–130 <0.001
CFU-GEMM 0 0–8 0 0–2 0.002
Total 86 20–246 17 3–330 <0.001
E:M ratio 0.64 0.13–2.30 0.17 0–6.3 0.01
CFU-G = Neutrophil colonies; CFU-M/GM = granulocyte/
macrophage colonies; CFU-Eo = eosinophil colonies; BFU-E = 
day 14 erythroid colonies; CFU-GEMM = mixed (erythroid/my-
eloid) colonies; E:M ratio = erythroid/myeloid ratio.
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BM controls BM patients PB controls PB patients
 Fig. 2. Total colony numbers per 100,000 BM and 600,000 PB 
cells, respectively, in 2-week cultures from healthy controls and 
MDS patients. Boxes represent median (horizontal line), 25th and 
75th percentile (edge of boxes), and whiskers represent minimal 
and maximal values. 
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last follow-up: 3 of these had received allogeneic stem cell 
transplantation early in the course of the disease.
 Importantly, if analysis was restricted to patients with 
an intermediate-risk IPSS score – the largest group of 
MDS patients and at the same time the subgroup in which 
therapeutic decisions are notoriously difficult – leukemic 
CFU-C growth retained its prognostic impact ( fig. 3 c). In 
IPSS low-risk patients, who in this cohort represent a to-
tal of 13 patients, leukemic growth at diagnosis was seen 
in 2 patients. Both patients transformed to AML early 
during follow-up (1 after 9 months, the other after 35 
months), while only one transformation to AML was seen 
in the other 11 IPSS low-risk patients without leukemic 
growth at initial diagnosis. 
 Impact of CFU-C Abnormalities on Transformation to 
AML in Univariate Analysis 
 Analysis of transformation to AML showed that leu-
kemic CFU-C growth at diagnosis was a strong predictor 
for early transformation to AML: transformation rate 
Table 2. Patient characteristics
Leukemic growth Quantitative growth
no 
(n = 34)
yes 
(n = 39)
p reduced 
(n = 34)
normal/increased 
(n = 39)
p
Age at diagnosis1, years 71 (23–87) 60 (13–88) 0.03 65 (33–88) 66 (17–88) 0.32
Gender
Male
Female
22 (64.7)
12 (35.3)
21 (53.8)
18 (46.2)
0.35 16 (61.5)
10 (38.5)
27 (57.4)
20 (42.6)
0.74
Etiology
Primary
Therapy related
28 (82.4)
6 (17.6)
34 (87.2)
5 (12.8)
0.83 22 (84.6)
4 (15.4)
40 (85.1)
7 (14.9)
0.84
WHO diagnosis
RA/RARS
RCMD/RCMD-RS
RAEB-1
RAEB-2
MDS-U
4 (11.8)
15 (44.4)
7 (20.6)
6 (17.6)
2 (5.9)
1 (2.6)
9 (23.1)
16 (41.0)
13 (33.3)
0 (0.0)
0.03 1 (3.8)
9 (34.6)
5 (19.2)
11 (42.3)
0 (0.0)
4 (8.5)
15 (31.9)
18 (38.3)
8 (17.0)
2 (4.3)
0.10
Cytogenetics
Good risk
Intermediate risk
Bad risk
27 (79.4)
4 (11.8)
3 (8.8)
20 (51.3)
7 (17.9)
12 (30.8)
0.03 18 (69.2)
4 (15.4)
4 (15.4)
29 (61.7)
7 (14.9)
11 (23.4)
0.71
Marrow cellularity
Hypoplastic
Normo/hypercellular
5 (14.7)
29 (85.3)
4 (10.3)
35 (89.7)
0.41 6 (23.1)
20 (76.9)
3 (6.4)
44 (93.6)
0.04
Marrow fibrosis
No
Yes
29 (85.3)
5 (14.7)
13 (33.3)
26 (66.7)
0.07 20 (76.9)
6 (23.1)
12 (25.5)
35 (74.5)
0.82
Serum LDH1 191 (128–385) 208 (100–1,224) 0.42 189 (121–699) 203 (100–1,224) 0.40
PB cytopenia
0–1 lineages
2–3 lineages
18 (52.9)
16 (47.1)
15 (38.5)
24 (61.5)
0.22 12 (46.2)
14 (53.8)
21 (44.7)
26 (55.3)
0.90
IPSS score
Low risk
Intermediate-1
Intermediate-2
High risk
11 (32.4)
16 (47.1)
6 (17.6)
1 (2.9)
2 (5.1)
17 (43.6)
14 (35.9)
6 (15.4)
0.001 4 (15.4)
11 (42.3)
7 (26.9)
4 (15.4)
9 (19.1)
22 (46.8)
13 (27.7)
3 (6.4)
0.65
Unless otherwise indicated figures represent number with the percentage in parentheses. RA = Refractory anemia; RARS = refrac-
tory anemia with ringed sideroblasts; RCMD = refractory cytopenia with multilineage dysplasia; RCMD-RS = refractory cytopenia 
with multilineage dysplasia and ringed sideroblasts; RAEB = refractory anemia with excess blasts; MDS-U = MDS unclassified.
1 Values represent median with the range in parentheses.
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 Fig. 3. Survival and transformation to AML in patients with MDS stratified by CFU-C growth at diagnosis: 
leukemic growth versus no leukemic growth in all patients ( a ,  b ) and in patients with intermediate-risk IPSS 
( c ,  d ).  e ,  f Survival and transformation rate in patients stratified according to reduced versus normal colony 
number. quant. = Quantitatively. 
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was 76  8 13% for patients with leukemic growth com-
pared to only 32  8 10% in patients without initial leuke-
mic growth ( fig. 3 b, p = 0.01). Again, leukemic growth 
retained its prognostic impact in patients with an inter-
mediate-risk IPSS ( fig. 3 d). Patients with reduced CFU-C 
growth on the other hand showed transformation rates 
comparable to those with quantitatively normal CFU-C 
assays (49  8 11 vs. 49  8 10%, p = 0.71,  fig. 3 f).
 Leukemic Growth Is an Independent Poor
Prognostic Factor 
 Multivariate analysis confirmed the results of univar-
iate analysis. Leukemic growth emerged as an indepen-
dent predictor of survival [relative risk (RR) 2.12, 95% 
confidence interval 1.08–4.16] and transformation to 
AML (RR 2.63, 95% CI 1.06–6.53,  table 3 ). The only oth-
er significant prognostic factor for both survival and 
transformation was cytogenetics. High marrow blast 
count and older age negatively influenced survival, and 
the presence of ringed sideroblasts was strongly protec-
tive against transformation while having only a statisti-
cally nonsignificant effect on survival. The quantity of 
CFU-C had no impact on survival and risk of transfor-
mation in multivariate analysis along with all other vari-
ables tested (marrow hypoplasia, marrow fibrosis, num-
ber of PB cytopenias, serum LDH, gender and etiology).
 Discussion 
 In this retrospective study including 73 patients with 
newly diagnosed MDS, quantitative and qualitative ab-
normalities of hematopoietic precursor cell colony growth 
were frequent: more than half of patients showed leuke-
mic cluster growth, whereas 1 out of 3 patients had strong-
ly reduced or absent colony growth. While leukemic clus-
ter growth was associated with other high-risk factors 
such as bad-risk cytogenetics and high marrow blast 
count, reduced colony growth was found more frequent-
ly in patients with hypoplastic marrow but was not asso-
ciated with any other commonly assessed risk factor. 
Only 2 patients had completely normal colony growth at 
diagnosis. Both were alive at 8 and 10 years of follow-up, 
respectively, without having received cytoreductive treat-
ment. 
 While having the limitation of being retrospective, 
this study with a long observation period allowed us to 
study the impact of abnormalities in quantitative and 
qualitative growth at first diagnosis on survival and risk 
of transformation. Leukemic cluster growth at diagnosis 
emerged as a highly sensitive predictor of transformation 
to AML and early death, whereas quantitative reduction 
of colony growth had no significant impact on the disease 
course. Multivariate analyses confirmed the significant 
Table 3. Multivariate analysis
Risk factor Survival Transformation
RR 95% CI p RR 95% CI p
CFU-C
No leukemic clusters 1.00 – – 1.00 – –
Leukemic clusters 2.12 1.08–4.16 0.03 2.63 1.06–6.53 0.04
Normal/increased growth 1.00 – – 1.00 – –
Reduced growth 0.77 0.38–1.56 0.47 0.80 0.30–2.13 0.66
Cytogenetics
Good risk 1.00 – – 1.00 – –
Intermediate risk 1.89 0.83–4.28 0.12 3.18 1.12–9.04 0.03
Bad risk 2.21 1.04–4.69 0.04 3.62 1.27–10.4 0.02
Blast count
<5% 1.00 – – 1.00 – –
6–10% 1.81 0.84–3.94 0.13 0.91 0.30–2.74 0.85
11–19% 2.17 0.96–4.90 0.06 1.97 0.67–5.83 0.22
Age at diagnosis
≤60 years 1.00 – – 1.00 – –
>60 years 1.97 1.04–3.74 0.04 1.22 0.53–2.78 0.65
Ringed sideroblasts
Not present 1.00 – – 1.00 – –
Present 0.63 0.28–1.43 0.27 0.16 0.03–0.77 0.02
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/1
0/
20
17
 1
:3
6:
22
 P
M
 Bernimoulin /Stern /Tichelli /Jotterand /
Gratwohl /Nissen 
Acta Haematol 2008;119:226–235234
value of leukemic cluster growth as a prognostic factor 
independent of other variables such as high marrow blast 
count and bad-risk cytogenetics. A limitation of our study 
is that patients referred to a tertiary center might not be 
entirely representative of the general population of pa-
tients with MDS, as younger patients and those with 
high-risk features may be more likely to be referred to a 
university hospital.
 Our results are in line with numerous early  [26, 28] 
and some more recent  [31, 35–37] studies on the prognos-
tic value of clonogenic assays in patients with MDS. The 
classification of MDS has undergone fundamental chang-
es in recent years: RAEB-t and chronic myelomonocytic 
leukemia, two former FAB entities where leukemic 
growth was typically found, are no longer classified as 
MDS. Our results underline that leukemic growth has an 
independent prognostic impact in patients classified ac-
cording to WHO and IPSS. These two classifications are 
widely used today to stratify patients into different risk 
groups and are useful to the clinician in defining an op-
timal treatment strategy, which can go from observation 
to early allogeneic stem cell transplantation. The fact that 
colony-forming cell assays identify a subpopulation at 
high risk of transformation and early death indicates that 
it may be of particular use in this situation. Our study 
further suggests that for young patients with leukemic 
growth at diagnosis, allogeneic transplantation should be 
considered early in the disease course, even if they are 
considered low or intermediate risk by IPSS: of 33 pa-
tients with leukemic growth, only 4 were alive at last fol-
low-up, 3 of whom had received allogeneic stem cell 
transplantation early in the disease course.
 Our study also demonstrates that diagnostic cultures 
using standard conditions and commercially available 
reagents have a high prognostic value. A recent compara-
tive study in our laboratory showed that, using nonsepa-
rated cell suspensions containing factor-producing ac-
cessory cells in standardized medium, leukemic growth 
is not factor dependent. While using growth factor-free 
medium and separation of progenitor and accessory cells 
have the advantage of elucidating pathological mecha-
nisms such as auto-/paracrine growth factor production 
involved in leukemic cluster growth, we chose simple cul-
ture conditions because of routine clinical feasibility. 
 Drawbacks of diagnostic cultures and reasons why 
they were widely abandoned were the technical difficul-
ties in preparing the media, lack of standardization, and 
the inevitable individual variability of different observ-
ers. However, up to now the culture technique has been 
simplified and internationally standardized mainly for 
the quantitative assay of functionally normal stem cells 
for stem cell transplantation. The same media can be 
used for detection of qualitative growth abnormalities. 
 In conclusion, we propose that precursor cell cultures 
deserve reappraisal as a valuable additional tool in the 
clinical management of MDS.  CFU-C cultures add a 
functional dimension to the standard morphological and 
cytogenetic criteria currently used to classify patients ac-
cording to WHO and IPSS. Most importantly, CFU-C 
cultures make it possible to identify a subgroup of pa-
tients at very high risk of disease progression and trans-
formation to AML. Leukemic growth as a reliable early 
sign of transformation to AML stresses the urgent need 
for aggressive therapy in patients eligible for it.
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